BridgeBio's BBP-418 FORTIFY Trial Delivers Positive Phase 3 Interim Data in LGMD2I/R9
BridgeBio Pharma has presented interim results from FORTIFY, its Phase 3 trial of oral BBP-418 in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The data, shared in a late-breaking oral presentation at the MDA Clinical and Scientific Conference in March 2026, showed separation from placebo on the 100-meter timed test (100MTT) as early as three months, with BBP-418-treated participants completing the test approximately 31 seconds faster than placebo at 12 months. Treatment also produced rapid and sustained reductions in serum creatine kinase, a biomarker of muscle damage, with 59.6% of participants achieving levels within twice the upper limit of normal at 12 months. The AllSci trial listing provides further detail on the study design.
Safety data were similarly consistent: adverse event rates were comparable between BBP-418 and placebo arms, with no treatment-related serious adverse events and no deaths. BridgeBio intends to submit a New Drug Application to the FDA for traditional approval in the first half of 2026, with a U.S. launch anticipated in late 2026 or early 2027. The company is also engaging European regulators to identify an expedited approval pathway. If approved, BBP-418 would be the first therapy cleared for LGMD2I/R9 and the first for any form of LGMD.
Research Context
The rationale for BBP-418 as a ribitol therapy for limb-girdle muscular dystrophy rests on a well-characterized disease mechanism. LGMD2I/R9 is caused by biallelic mutations in the FKRP gene, which encodes a glycosyltransferase responsible for adding ribitol-5-phosphate to the sugar chain on alpha-dystroglycan. Hypoglycosylation of alpha-dystroglycan disrupts the structural link between the muscle cell membrane and the extracellular matrix, leading to progressive muscle degeneration. Most FKRP mutations are hypomorphic, meaning residual enzymatic activity persists. BBP-418 exploits this by providing supraphysiological levels of ribitol substrate, driving the mutant enzyme to restore glycosylation. Preclinical work in FKRP P448L mutant rodent models demonstrated that ribitol supplementation increased glycosylated alpha-dystroglycan levels, and a high-throughput cell-based assay presented at MDA by researchers at Yale School of Medicine now provides a scalable framework for evaluating ribitol responsiveness across the full spectrum of FKRP variants.
No FDA-approved disease-modifying therapies exist for LGMD2I/R9 or any LGMD subtype. Current management is entirely supportive: physical and occupational therapy, assistive devices, cardiac monitoring with ACE inhibitors or beta-blockers, and respiratory support including non-invasive ventilation. A systematic literature review presented by BridgeBio at MDA confirmed substantial clinical burden and elevated healthcare costs among individuals with LGMD2I/R9, while highlighting gaps in data on economic and caregiver burden. The recent introduction of a specific ICD-10-CM code (G71.036) for LGMD2I/R9 is expected to improve patient identification and enable more robust real-world research. A health outcomes model presented alongside the BBP-418 Phase 3 results showed that LGMD2I/R9 is associated with reduced life years and quality-adjusted life years, driven primarily by cardiomyopathy and loss of ambulation.